نتائج البحث - "Hélène Blasco"

1

Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model

المؤلفون: Christian R. Andres, G Bacle, Patrick Vourc'h, Charlotte Veyrat-Durebex, Patrick Emond, Antoine Lefèvre, Débora Lanznaster, Hélène Blasco, François Maillot, Jean-Baptiste Delaye, P. Corcia, J C Lecron, A Fontaine, Rudolph Hergesheimer

المصدر: Neurotherapeutics

مصطلحات موضوعية: Leptin, Male, 0301 basic medicine, medicine.medical_specialty, FGF21, Arginine, medicine.medical_treatment, Mice, Transgenic, Stimulation, Serine, Mice, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Animals, Metabolomics, Resistin, Pharmacology (medical), Amyotrophic lateral sclerosis, Chemokine CCL2, Pharmacology, Interleukin-6, Tumor Necrosis Factor-alpha, business.industry, Insulin, Amyotrophic Lateral Sclerosis, Antibodies, Monoclonal, medicine.disease, Fibroblast Growth Factors, Mice, Inbred C57BL, Disease Models, Animal, Metabolic pathway, 030104 developmental biology, Endocrinology, Rotarod Performance Test, Original Article, Neurology (clinical), Transcriptome, business, 030217 neurology & neurosurgery, Homeostasis, Signal Transduction

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2720ed6df34136797a1e83e3c607b373Test
https://doi.org/10.1007/s13311-020-00933-3Test

2

Understanding and managing metabolic dysfunction in Amyotrophic Lateral Sclerosis

المؤلفون: Patrick Vourc'h, P. Corcia, Christian R. Andres, Rudolf Hergesheimer, Pierre-François Pradat, Hélène Blasco, François Maillot, Débora Lanznaster, Charlotte Veyrat-Durebex

المصدر: Expert review of neurotherapeutics. 20(9)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5880447c46b1eb3d7c6642b27cd8b94aTest
https://pubmed.ncbi.nlm.nih.gov/32583696Test

3

Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis

المؤلفون: Patrick Vourc'h, Rudolph Hergesheimer, Se Bakkouche, Hélène Blasco, Philippe Corcia, Stéphane Beltran, Cr Andres, Débora Lanznaster, P. Couratier

المساهمون: Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre de compétence de la Sclérose Latérale Amyotrophique [CHRU Tours] (SLA CHRU Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Neurologie [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: Expert Opinion on Pharmacotherapy
Expert Opinion on Pharmacotherapy, Taylor & Francis, 2020, 21 (9), pp.1103-1110. ⟨10.1080/14656566.2020.1746270⟩

مصطلحات موضوعية: Oncology, Drug, medicine.medical_specialty, media_common.quotation_subject, Disease, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Edaravone, clinical staging, Medicine, Humans, Pharmacology (medical), Amyotrophic lateral sclerosis, media_common, Pharmacology, dexpramipexole, edaravone, business.industry, Amyotrophic Lateral Sclerosis, biomarkers, General Medicine, personalized medicine, medicine.disease, 3. Good health, Riluzole, Clinical trial, Neuroprotective Agents, chemistry, 030220 oncology & carcinogenesis, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Personalized medicine, ALS, business, Dexpramipexole, 030217 neurology & neurosurgery, medicine.drug